Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia

DISEASE CHARACTERISTICS:

Diagnosis of 1 of the following:

CD20-positive aggressive B-cell non-Hodgkin's lymphoma (NHL), including any of the following subtypes:

Diffuse large cell lymphoma*, meeting 1 of the following criteria:

Relapsed disease after initial therapy, but failed to mobilize or had bone marrow involvement and therefore is not suitable for an autologous stem cell transplantation
High-intermediate- or high-risk second-line, age-adjusted International Prognostic Index score and in second complete remission (CR) or partial remission (PR) after autologous stem cell transplantation
Failed prior autologous stem cell transplantation and in PR or better after salvage chemotherapy

Large cell transformation of indolent NHL or chronic lymphocytic leukemia (CLL), meeting the following criteria:

In CR or PR of the large cell component of disease after salvage chemotherapy or autologous stem cell transplantation

Mantle cell lymphoma*, meeting 1 of the following criteria:

High-risk disease (e.g., p53 positivity) and in first CR or PR after initial therapy
Relapsed disease after initial therapy and in second or third CR or PR after salvage chemotherapy NOTE: *No progressive disease at allograft work-up

CD20-positive indolent NHL (e.g., follicular lymphoma, small cell lymphoma, or marginal zone NHL) OR CLL

Second or subsequent progression (pre-allograft cytoreduction necessary, but CR or PR not required)
Relapsed disease must be biopsy-proven

Must have received pre-allograft salvage chemotherapy, including 1 of the following:

Single autologous stem cell transplantation using high-dose chemotherapy conditioning within the past 120 days
At least 2 courses of intensive combination chemotherapy (e.g., RICE [rituximab, ifosfamide, carboplatin, etoposide]), according to diagnosis, within the past 80 days
CLL patients who have received CAMPATH do not have to receive pre-allograft salvage chemotherapy

HLA-compatible related or unrelated donor available

HLA-matched ≥ 9/10 of the A, B, C, DRB1, and DQB1 loci, as tested by high resolution typing

One allele mismatch allowed

PATIENT CHARACTERISTICS:

Karnofsky performance status 70-100%
Creatinine < 1.2 mg/mL OR creatinine clearance ≥ 50 mL/min
Bilirubin < 2.5 mg/dL
AST and ALT ≤ 3 times upper limit of normal (unless benign congenital hyperbilirubinemia is present)
Spirometry and corrected DLCO ≥ 50% of normal
LVEF ≥ 40%
Albumin ≥ 2.5 g/dL
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No active uncontrolled infection, including active infection with Aspergillus or other mold
No HIV infection
No hepatitis B antibody or antigen positivity

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
No prior allogeneic transplantation